<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336388">
  <stage>Registered</stage>
  <submitdate>10/01/2011</submitdate>
  <approvaldate>12/01/2011</approvaldate>
  <actrnumber>ACTRN12611000038998</actrnumber>
  <trial_identification>
    <studytitle>Effect of endotracheal tube on ventilator associated pneumonia in Intensive Care Unit patients</studytitle>
    <scientifictitle>Effect of EVAC endotracheal tube on decreasing ventilator associated pneumonia  in critically ill patients admitted to Intensive Care Units</scientifictitle>
    <utrn>U1111-1118-9359</utrn>
    <trialacronym />
    <secondaryid>Trial has not a secondary ID.</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pneumonia</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intubation of patients with EVAC oral endotracheal tube.(A specific tube with a distal lumen for suctioning of subglottic secretions and very thin cuff with poly urethane material which has not any folds on it after cuff filling). Patients will be intubated minimum 3 days until they will meet extubation criteria.</interventions>
    <comparator>Intubation of patients with standard oral endotracheal tubes(Polyvinyl Chloride portex tubes with high volum and low pressure cuff),and will be intubated minimum 3 days until they will meet extubation criteria.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ventilator Associated Pneumonia will be assessed by CIPS(Clinically infectione Pulmonary Score).If the score is more than 6 the patient has VAP.</outcome>
      <timepoint>During Intensive Care Unit(ICU) stay</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality</outcome>
      <timepoint>During Intensive Care Unit Stay</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients(more than 18 years old) who will be ventilated for more than 3 days</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>previous history of mechanical ventilation,pregnancy, Human Immunodefficiency Virus infection, malignancy,Immunosuppressive therapy, leukocyte count less than 1000/mm3</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tabriz University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Golgasht street, Tabriz
5157663114</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tabriz University of Medical Sciences</fundingname>
      <fundingaddress>Golgasht street, Tabriz
5157663114</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Almost 10-28% of patients admitted to intensive Care Units(ICU) suffered from Ventilator Associated Pneumonia(VAP) which leads to increasing mortality,ICU length of stay and mortality. As micro or macroaspiration of subglottic secretions is one of the most important risk factors for developing VAP, adevice that can suction these secretion may help to decreasing VAP. So in this study we want to evaluate the efficacy of EVAC endotracheal tube in decreasing VAP in critical ill patients.
ninty patients will be enrolled in this study. patient will be allocated to two 45 patient groups. One group will be intubated with EVAC endotracheal tube and the other group will be intubated with standard tube. the Vap rate, mortality, ICU length of stay and duration of mechanical ventilation will be noted for each patient.</summary>
    <trialwebsite>there is not any website for trial</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of Tabriz Medical University</ethicname>
      <ethicaddress>University of Tabriz,Daneshgah street, Tabriz
515766114</ethicaddress>
      <ethicapprovaldate>11/12/2010</ethicapprovaldate>
      <hrec>5/04/7376</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ata Mahmoodpoor</name>
      <address>General ICU, Shohada hospital,El-Goli ave, Tabriz</address>
      <phone>00989141160888</phone>
      <fax />
      <email>amahmoodpoor@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>ata mahmoodpoor</name>
      <address>General ICU, Shohada hospital,El-Goli ave, Tabriz
5157663114</address>
      <phone>00989141160888</phone>
      <fax />
      <email>amahmoodpoor@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Masoud Hamidi</name>
      <address>General ICU, Shohada hospital,El-Goli ave, Tabriz
5157663114</address>
      <phone>00989144144417</phone>
      <fax />
      <email>masoodhamidi59@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>